Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Disc Medicine presented updated positive Phase 2 data for DISC-0974 in myelofibrosis-associated anemia at the ASCO Annual Meeting. The trial showed durable anemia responses across all patient subgroups, including those receiving concomitant JAK inhibitor therapy, with >75% hepcidin reduction and significant improvements in transfusion burden and fatigue. Major response rates ranged from 50% to 64% depending on baseline transfusion status, supporting the drug's potential in a broad patient population with substantial unmet need.
Key figures
- Drug Name
- DISC-0974
- Phase Of Trial
- Phase 2
- Total enrolled
- 61
- Hepcidin reduction
- >75%
- Responder analysis n
- 50
- N TD major response rate
- 55%
- N TD overall response rate
- 68%
- TD Low overall response rate
- 73%
- TD High overall response rate
- 88%
- JAK inhibitor major response rate
- 56%
- JAK inhibitor overall response rate
- 72%
- TD Low transfusion independence rate
- 64%
- TD High transfusion independence rate
- 50%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.